Veeva Systems (NYSE: VEEV) announced Veeva Falcon, an artificial intelligence platform designed to automate processes in drug development. The platform integrates with Veeva Development Cloud applications across clinical, regulatory, and safety functions.

Falcon initially targets three areas: trial master file document intake and quality control, health authority correspondence in regulatory processes, and safety case triage and intake. The platform is scheduled for early adopter availability in November 2026.

"Falcon is a major initiative for Veeva and our first offering in agentic labor," said Peter Gassner, founder and CEO of Veeva Systems. "I'm excited to partner with customers and help the industry lower costs and increase speed in drug development with Falcon."

The platform represents Veeva's entry into what the company terms "agentic labor" - automated systems that can perform tasks typically requiring human intervention. Falcon operates as part of Veeva AI, the company's suite of artificial intelligence solutions for life sciences.

Veeva Systems provides cloud-based software solutions for pharmaceutical and biotechnology companies. The company serves more than 1,500 customers ranging from large pharmaceutical companies to emerging biotechnology firms.

The announcement was made through a company press release on May 27, 2026.